$NWBO News

Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility

Northwest Biotherapeutics: Q3 Earnings Snapshot

Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed

Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

Northwest Biotherapeutics: Q2 Earnings Snapshot

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

Northwest Biotherapeutics: Q1 Earnings Snapshot

Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

Northwest Biotherapeutics: All Is Not Well With This One

Northwest Biotherapeutics: Q3 Earnings Snapshot

Northwest Biotherapeutics: Q2 Earnings Snapshot

Northwest Biotherapeutics Addresses Market Rumor Concerns

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

Northwest Biotherapeutics announces exclusive license from Roswell Park

'$NWBO granted millions of stock options to insiders the day before DCVax paper published. But sure, keep banging on about naked shorts.'-STAT's Adam Feuerstein Tweets

Northwest Biotherapeutics Shares Quiet Following 13G Filing Disclosing 7% Stake by Capital Ventures

Northwest Biotherapeutics Prices ~4.895M Units at $4.80/Unit, Expecting Gross Proceeds $23.5M, Warrants for $6/Share

Northwest Biotherapeutics Files Prospectus Supplement for Stocks, Warrants